Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency

Next Previous
X
Search
Trial Profile

Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Carcinoma; Endometrial cancer; Sarcoma; Solid tumours
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 Sep 2023 Status changed from active, no longer recruiting to completed.
    • 12 Jan 2021 Status changed from recruiting to active, no longer recruiting.
    • 04 Jun 2019 Results (n=42) assessing Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab presented at the 55th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top